Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This proposal details the implementation of an international (Singapore and New Zealand)
multi-centre study to test a novel therapeutic strategy aimed at reducing the burden of
atrial fibrillation - an important medical condition with major healthcare implications.
Unique aspects of this study include i) a non-arrhythmic treatment target (mineralocorticoid
receptor antagonism) -targeting the arrhythmogenic substrate of AF before it becomes
permanently established, ii) the use of pacemaker monitoring capability to accurately
document AF burden, thus increasing the power of the study and iii) multi-national
collaborative, double blind design.